InsiderTrades

KLRA Kailera Therapeutics, Inc.

Nasdaq · SEC CIK 2096997 · EDGAR

Bought, last 12 months
$326.75M
5 purchases by 5 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Filings on record
20
since 2026-04-20, latest 2026-09-09 19:29
Buying vs selling by month open-market trades, last 24 months
BoughtSold

Most active insiders, 12 months

InsiderTitleBoughtSold
Kaplan Andrew T.Dir, 10% $134.38M—
BAIN CAPITAL INVESTORS LLC10% $134.38M—
Bain Capital Life Sciences Investors, LLC10% $25.00M—
Koppel AdamDir, 10% $25.00M—
RTW INVESTMENTS, LP10% $8.00M—
Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% ——
Renaud Ronald C JRCEO, Pres, Dir ——

Transactions 12

Type
Reset
X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-06-11 16:05 2026-06-09 KLRA Renaud Ronald C JR CEO, Pres, Dir M - OptEx $5.25 +38.1K 38.1K New +$200.0K
DI 2026-04-22 16:15 2026-04-20 KLRA RTW INVESTMENTS, LP 10% C - Cnv Deriv — +10.28M 10.28M New —
DI 2026-04-22 16:15 2026-04-20 KLRA RTW INVESTMENTS, LP 10% P - Purchase $16.00 +500.0K 10.78M +5% +$8.00M
DM 2026-04-22 06:03 2026-04-20 KLRA Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% C - Cnv Deriv — +11.51M 2.03M New —
DI 2026-04-20 18:10 2026-04-20 KLRA BAIN CAPITAL INVESTORS LLC 10% C - Cnv Deriv — +17.86M 17.86M New —
DI 2026-04-20 18:10 2026-04-20 KLRA BAIN CAPITAL INVESTORS LLC 10% P - Purchase $16.00 +8.40M 26.26M +47% +$134.38M
DMI 2026-04-20 18:08 2026-04-20 KLRA Koppel Adam Dir, 10% C - Cnv Deriv — +21.02M 21.02M New —
DI 2026-04-20 18:08 2026-04-20 KLRA Koppel Adam Dir, 10% P - Purchase $16.00 +1.56M 22.58M +7% +$25.00M
DMI 2026-04-20 18:01 2026-04-20 KLRA Bain Capital Life Sciences Investors, LLC 10% C - Cnv Deriv — +21.02M 21.02M New —
DI 2026-04-20 18:01 2026-04-20 KLRA Bain Capital Life Sciences Investors, LLC 10% P - Purchase $16.00 +1.56M 22.58M +7% +$25.00M
DI 2026-04-20 18:00 2026-04-20 KLRA Kaplan Andrew T. Dir, 10% C - Cnv Deriv — +17.86M 17.86M New —
DI 2026-04-20 18:00 2026-04-20 KLRA Kaplan Andrew T. Dir, 10% P - Purchase $16.00 +8.40M 26.26M +47% +$134.38M

Purchase Sale Sale after option exercise All abbreviations